Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

Fulvestrant is a pure estrogen receptor (ER) antagonist approved for the treatment of metastatic ER positive breast cancer in postmenopausal women with disease progression following antiestrogen therapy. The clinical results of fulvestrant demonstrated encouraging activity in tumors in spite of HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusz, Orsolya, Kószó, Renáta, Dobi, Ágnes, Csenki, Melinda, Valicsek, Erzsébet, Nikolényi, Alíz, Uhercsák, Gabriella, Cserháti, Adrienne, Kahán, Zsuzsanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129034/
https://www.ncbi.nlm.nih.gov/pubmed/30233207
http://dx.doi.org/10.2147/OTT.S170736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129034/
https://www.ncbi.nlm.nih.gov/pubmed/30233207
http://dx.doi.org/10.2147/OTT.S170736

Ejemplares similares